Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
First Hospitalized COVID-19 Patient Treated with the Antibody Drug Candidate COR-101
Details : COR-101 is a fully human IgG monoclonal antibody isolated from recovered COVID-19 patients. COR-101 prevents SARS-CoV-2 from infecting new cells by binding the surface of the virus thereby preventing that the virus attaches to human cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : COR-101 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : COR-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
